Heparin vs Enoxaparin

Heparin and enoxaparin are both anticoagulants that enhance antithrombin III (ATIII) activity, but they differ fundamentally in molecular weight, pharmacokinetics, and clinical application. Unfractionated heparin (UFH) is a heterogeneous mixture of sulfated glycosaminoglycan chains ranging from 3,000–30,000 Da, while enoxaparin is a low-molecular-weight heparin (LMWH) produced by controlled depolymerization, averaging ~4,500 Da. These molecular weight differences produce distinct anticoagulation profiles, monitoring requirements, and safety considerations.

Chemical Identity

Unfractionated Heparin (UFH)

• Source: Porcine intestinal mucosa or bovine lung
• Structure: Sulfated glycosaminoglycan polymer
• Average molecular weight: 12,000–15,000 Da (range: 3,000–30,000 Da)
• Composition: Repeating disaccharide units of D-glucosamine and D-glucuronic acid
• Sulfation: Heavy sulfation (N-sulfate and O-sulfate groups)
• Charge density: Highest among known biomolecules
• Potency: ~180 USP units/mg

Enoxaparin (LMWH)

• Source: Porcine intestinal mucosa (depolymerized UFH)
• Structure: Depolymerized sulfated glycosaminoglycan
• Average molecular weight: 4,500 Da (range: 2,000–8,000 Da)
• Preparation: Benzoylation followed by alkaline hydrolysis (produces 1,6-anhydro ring at reducing end)
• Unique feature: Contains 2-O-sulfo-α-L-iduronic acid at non-reducing end
• Potency: ~100 anti-Xa IU/mg

Property	UFH	Enoxaparin
Molecular weight	12,000–15,000 Da	~4,500 Da
Chain length	40–50 saccharide units	8–15 saccharide units
Sulfation	Heavy	Moderate
Bioavailability (SC)	~30%	~90%
Half-life	1–2 hours	4–5 hours
Dose response	Variable	Predictable

Mechanism of Action

ATIII Enhancement

Both heparin and enoxaparin work by binding antithrombin III (ATIII) and enhancing its inhibitory activity against coagulation serine proteases.

UFH: Dual Mechanism (Anti-IIa + Anti-Xa)

UFH binds ATIII via a specific pentasaccharide sequence, inducing a conformational change that accelerates ATIII’s inhibition of:

1. Thrombin (Factor IIa): Requires simultaneous binding of heparin to both ATIII and thrombin (template mechanism)
2. Factor Xa: Only requires heparin-ATIII binding (no template needed)
3. Additional targets: Inhibits Factors IXa, XIa, XIIa, and XIIa

For thrombin inhibition, UFH must span at least 18 saccharide units (~5,400 Da) to form the ternary heparin-ATIII-thrombin complex. This creates a 1:1 stoichiometric relationship.

Enoxaparin: Predominantly Anti-Xa

Enoxaparin’s shorter chains limit template formation:

1. Factor Xa inhibition: Enhanced (ATIII-mediated, no template needed)
2. Thrombin inhibition: Reduced (only ~25% of chains are long enough for template mechanism)
3. Anti-Xa:IIa ratio: ~2.7:1 (vs. 1:1 for UFH)

Anti-Xa:IIa Ratio

Parameter	UFH	Enoxaparin
Anti-Xa activity	1.0 IU/mg	1.0 IU/mg
Anti-IIa activity	1.0 IU/mg	0.4 IU/mg
Anti-Xa:IIa ratio	1:1	2.7:1
Thrombin inhibition	Strong	Partial
Fibrin-bound thrombin	Inhibited	Poorly inhibited
Platelet factor 4 resistance	Sensitive	Partially resistant

Additional Anticoagulant Mechanisms

• UFH: Releases TFPI from endothelium, inhibits platelet aggregation (high doses)
• Enoxaparin: Releases TFPI, modest anti-inflammatory effects, less platelet interaction
• Both: Enhance fibrinolysis (tPA release), inhibit smooth muscle proliferation

Pharmacokinetics

UFH: Unpredictable, Protein-Bound

Parameter	Value
IV onset	Immediate
SC onset	1–2 hours
Half-life	1–2 hours (dose-dependent)
Bioavailability (SC)	~30%
Vd	0.06 L/kg (confined to blood)
Protein binding	95% (to albumin, histidine-rich glycoprotein)
Clearance	Reticuloendothelial system (macrophages), hepatic heparanase
Elimination	Non-linear (saturable)
Duration	4–6 hours (IV bolus)

UFH exhibits non-linear pharmacokinetics due to saturable binding to plasma proteins, endothelial cells, and macrophages. This produces highly variable anticoagulant responses between patients.

Enoxaparin: Predictable, Dose-Linear

Parameter	Value
SC onset	3–5 hours
Half-life	4–5 hours
Bioavailability (SC)	~90%
Vd	0.07 L/kg
Protein binding	Minimal
Clearance	Renal (glomerular filtration)
Elimination	Linear (dose-proportional)
Duration	12 hours

Enoxaparin demonstrates near-complete subcutaneous bioavailability and predictable, dose-linear pharmacokinetics. This eliminates the need for routine monitoring.

Monitoring

UFH: aPTT Monitoring Required

UFH requires routine monitoring due to variable dose-response:

• Test: Activated partial thromboplastin time (aPTT)
• Target: 1.5–2.5× control (approximately 60–80 seconds)
• Monitoring frequency: Every 6 hours until therapeutic, then every 24 hours
• Anti-Xa level (alternative): 0.3–0.7 IU/mL (for UFH)
• ACT (procedures): >400 seconds (cardiac surgery, PCI)
• Platelet count: Every 2–3 days (heparin-induced thrombocytopenia screening)

Enoxaparin: No Routine monitoring

Enoxaparin generally does not require monitoring:

• Routine monitoring: Not recommended (predictable pharmacokinetics)
• Anti-Xa monitoring: Reserved for special populations:
  • Renal impairment (CrCl < 30 mL/min)
  • Obesity (> 120 kg)
  • Pregnancy
  • Pediatric patients
  • Extreme low weight (< 45 kg)
• Target anti-Xa (when monitored): 0.5–1.0 IU/mL (twice-daily dosing)
• Anti-Xa timing: 4 hours post-dose (peak level)
• Platelet count: Baseline and day 4 (HIT screening)

Monitoring Comparison

Parameter	UFH	Enoxaparin
Routine monitoring	Required	Not required
Primary test	aPTT	Anti-Xa (special cases only)
Target range	1.5–2.5× control	0.5–1.0 IU/mL
Monitoring frequency	Every 6–24 hours	Only in special populations
Dose adjustment	Frequent	Rare
Heparin-PF4 assay	Monitor q2–3 days	Baseline + day 4

Onset and Dosing

UFH

Route	Onset	Duration	Typical Dose
IV bolus	Immediate	4–6 hours	80 units/kg bolus
IV infusion	1–5 minutes	Per infusion rate	18 units/kg/hour
SC prophylaxis	1–2 hours	8–12 hours	5,000 units q8–12h
Therapeutic SC	1–2 hours	8–12 hours	5,000 units initial, then adjusted

Enoxaparin

Route	Onset	Duration	Typical Dose
SC prophylaxis	3–5 hours	12–24 hours	30 mg q12h or 40 mg q24h
SC therapeutic	3–5 hours	12 hours	1 mg/kg q12h
ACS (STEMI)	3–5 hours	12 hours	1 mg/kg q12h
Renal dose	3–5 hours	24 hours	1 mg/kg q24h (CrCl < 30)

Dosing Comparison

Parameter	UFH	Enoxaparin
Typical route	IV or SC	SC only
Therapeutic dose	80 U/kg bolus → 18 U/kg/h	1 mg/kg q12h
Prophylactic dose	5,000 U q8–12h SC	40 mg q24h SC
Dose adjustment	Frequent (per aPTT)	Rare
Renal adjustment	Not required	Extend interval (q24h)
Obese patients	Weight-based IV	1 mg/kg (use actual weight)

Reversal

UFH: Protamine Sulfate

Protamine sulfate is a positively charged protein that binds negatively charged heparin:

• Mechanism: Ionic binding to heparin, neutralizing anticoagulant activity
• Dose: 1 mg protamine neutralizes 100 units heparin
• Maximum dose: 50 mg (given slowly IV over 10 minutes)
• Reversal efficiency: ~100% (if given within 30 minutes of heparin dose)
• Timing-dependent: Decreasing effectiveness as heparin is cleared
• Heparin half-life: 30–60 minutes → complete reversal within 5 minutes of administration

Enoxaparin: Incomplete Reversal with Protamine

Protamine provides partial reversal of enoxaparin:

• Mechanism: Protamine neutralizes anti-IIa activity of enoxaparin
• Anti-Xa neutralization: Only ~60% of anti-Xa activity is neutralized
• Clinical implication: Incomplete reversal; continued anticoagulant effect persists
• Dose: 1 mg protamine per 1 mg enoxaparin
• Maximum dose: 50 mg
• Timing: Must be given within 8 hours of last enoxaparin dose

Reversal Comparison

Parameter	UFH	Enoxaparin
Reversal agent	Protamine sulfate	Protamine sulfate (partial)
Reversal completeness	~100%	~60% (anti-IIa); partial (anti-Xa)
Dose	1 mg per 100 U heparin	1 mg per 1 mg enoxaparin
Time window	Up to 30 min post-dose	Up to 8 hours post-dose
Onset of reversal	5 minutes	5 minutes
Duration of effect	Permanent (heparin cleared)	Anti-Xa effect persists
Emergency bypass	Effective	Limited

Side Effects

Shared Side Effects

• Bleeding (dose-dependent)
• Injection site hematoma, pain, erythema
• Hypersensitivity (rare)
• Osteoporosis (long-term use > 6 months)

UFH-Specific

• Heparin-induced thrombocytopenia (HIT): Immune-mediated (Type II), 1–5% incidence; IgG antibody against PF4-heparin complex
• Hyperkalemia: Aldosterone suppression (Type IV RTA)
• Alopecia: Rare, reversible
• Transaminase elevation: Transient, benign
• Skin necrosis: Heparin-induced skin necrosis (rare, associated with HIT)

Enoxaparin-Specific

• HIT incidence: Lower (~0.2–1%) compared to UFH
• Elevated transaminases: ~5% (usually mild, reversible)
• Less hyperkalemia: Compared to UFH
• Skin nodules: Injection site nodules (self-limiting)
• Spinal/epidural hematoma: Risk with neuraxial anesthesia (FDA black box warning)

Clinical Positioning

UFH Preferred When

• Rapid onset/reversal is critical (cardiac surgery, vascular surgery)
• Renal failure (not renally cleared)
• Atrial fibrillation cardioversion (rapid reversal)
• Thrombolysis for STEMI (adjunct)
• HIT management (argatroban, bivalirudin)
• Patients with severe obesity (predictable IV dosing)

Enoxaparin Preferred When

• DVT prophylaxis (medical/surgical patients)
• Outpatient anticoagulation (no monitoring needed)
• ACS management (NSTE-ACS, STEMI without PCI)
• Stroke prevention in atrial fibrillation (non-valvular)
• Cancer-associated thrombosis
• Bridging therapy for warfarin discontinuation

Clinical Positioning Summary

Indication	UFH	Enoxaparin
DVT prophylaxis (surgical)	Yes	Preferred
DVT prophylaxis (medical)	Yes	Preferred
Therapeutic DVT/PE	Yes	Preferred
ACS (STEMI)	Yes	Yes
ACS (NSTE-ACS)	Yes	Preferred
Cardiac surgery	Preferred	Contraindicated
Renal failure	Preferred	Dose-adjust
HIT history	Preferred (if needed)	Avoid
Outpatient use	No	Preferred
Bridging therapy	Yes	Preferred

Cost and Access

Parameter	UFH	Enoxaparin
Generic availability	Yes	Yes
Cost (relative)	Low	Moderate
Monitoring cost	High (frequent aPTT)	Low (minimal monitoring)
Total cost of care	Moderate	Low-moderate
Hospital pharmacy	IV bags, infusion pumps	Prefilled syringes
Administration	IV/SC (requires training)	SC (patient self-inject)

References

1. Hirsh J, et al. “Heparin and low-molecular-weight heparin.” Chest 2008;133:185S-215S.
2. Weitz JI. “Low-molecular-weight heparins.” N Engl J Med 1997;337:688-698.
3. Garcia DA, et al. “Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis.” Chest 2012;141:e24S-e43S.
4. Baroletti S, et al. “Heparin-induced thrombocytopenia.” Arch Intern Med 2004;164:1565-1569.
5. Nieuwenhuis HK, et al. “Heparin-induced thrombocytopenia.” Thromb Haemost 2001;86:599-606.